NCT05549778View on ClinicalTrials.gov

Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

January 20, 2023

Study Completion Date

January 31, 2023

Conditions
Castration-resistant Prostate Cancer
Interventions
DRUG

Polaprezinc group

Abiraterone plus Polaprezinc for 6 months

DRUG

Control group

Abiraterone, radio- or chemotherapy

Trial Locations (1)

214000

Jiangnan University, Wuxi

All Listed Sponsors
collaborator

Affiliated Hospital of Jiangnan University

OTHER

lead

Jiangnan University

OTHER

NCT05549778 - Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC | Biotech Hunter | Biotech Hunter